Granules India’s wholly owned subsidiary - Granules Pharmaceuticals, Inc., (GPI) has entered into an agreement with USpharma, based in the USA, to acquire 12.5% of its stake. This investment will enable Granules to participate in product selection and have right of first refusal to market the select products which are under development by USpharma.
USpharma is a development-stage pharmaceutical company specializing in research, development and manufacture of high entry-barrier generic pharmaceuticals, including controlled-release, controlled- substance and patent-challenge products. USpharma in collaboration with manufacturing partners had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been out licensed to Granules exclusively.
USpharma has formulation development and manufacturing facilities in Philadelphia, Pennsylvania, USA, Mumbai, India and cGMP analytical laboratory in Kansas City, Missouri, USA.
Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.
